JP2013533747A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013533747A5 JP2013533747A5 JP2013518813A JP2013518813A JP2013533747A5 JP 2013533747 A5 JP2013533747 A5 JP 2013533747A5 JP 2013518813 A JP2013518813 A JP 2013518813A JP 2013518813 A JP2013518813 A JP 2013518813A JP 2013533747 A5 JP2013533747 A5 JP 2013533747A5
- Authority
- JP
- Japan
- Prior art keywords
- particle
- rna
- immunogen
- particles
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Description
PKRは、二本鎖RNA依存性プロテインキナーゼである。これは、先天的免疫系において重要な役割を果たす。「EIF2AK2」(真核生物翻訳開始因子2−αキナーゼ2(eukaryotic translation initiation factor 2−alpha kinase 2)について)は、この酵素をコードする遺伝子の承認されたHGNC名であり、その特有のHGNC IDは、HGNC:9437である。ヒトPKR遺伝子のRefSeq配列は、GI:208431825である。
特定の実施形態では、例えば以下が提供される:
(項目1)
脊椎動物細胞へRNAをインビボで送達するための非ビリオン粒子であって、ここで、
(a)該粒子は、
(i)送達物質であって、免疫原をコードする自己複製RNA分子を被包している、送達物質、または
(ii)送達物質であって、免疫原をコードする自己複製RNA分子が、該送達物質に吸着させられている、送達物質
のいずれかを含み、
(b)該RNAは、改変されたヌクレオチドを含まない、
非ビリオン粒子。
(項目2)
前記粒子が、リポソームであり、前記RNAが、該リポソーム中に被包されている、項目1に記載の粒子。
(項目3)
前記粒子が、非毒性かつ生分解性のポリマー微粒子であり、前記RNAが、該ポリマー微粒子に吸着させられている、項目1に記載の粒子。
(項目4)
前記粒子が、ポリマー、架橋剤、荷電したモノマーおよび前記RNAを反応させることによって形成された、生分解性の架橋されたオリゴマーのポリマーナノ粒子である、項目1に記載の粒子。
(項目5)
前記リポソームが、カチオン性頭部を有する脂質を含む、項目2に記載の粒子。
(項目6)
前記リポソームが、両性イオン性頭部を有する脂質を含む、項目2または項目5に記載の粒子。
(項目7)
前記リポソームが、50nm〜220nmの範囲の直径を有する、項目2、項目5または項目6に記載の粒子。
(項目8)
前記粒子が、ポリ(D,L−ラクチド−co−グリコリド)を含む、項目3に記載の粒子。
(項目9)
前記粒子が、直径30nm〜7μmを有する、項目3または項目8に記載の粒子。
(項目10)
前記自己複製RNA分子が、
(i)該自己複製RNA分子からRNAを転写し得るRNA依存性RNAポリメラーゼ、および
(ii)免疫原
をコードする、前述の項目のいずれかに記載の粒子。
(項目11)
前記RNA分子が、2個のオープンリーディングフレームを有し、該2個のオープンリーディングフレームの第1のものが、アルファウイルスレプリカーゼをコードし、該2個のオープンリーディングフレームの第2のものが、前記免疫原をコードする、項目10に記載の粒子。
(項目12)
前記RNA分子が、9000〜12000ヌクレオチド長である、前述の項目のいずれかに記載の粒子。
(項目13)
前記免疫原が、細菌、ウイルス、真菌もしくは寄生生物に対してインビボで免疫応答を誘
発し得る、前述の項目のいずれかに記載の粒子。
(項目14)
前記免疫原が、RSウイルス糖タンパク質Fに対してインビボで免疫応答を誘発し得る、項目13に記載の粒子。
(項目15)
前述の項目のいずれかに記載の粒子を含む、薬学的組成物。
(項目16)
脊椎動物において防御免疫応答を惹起するための方法であって、該方法は、項目1〜14に記載の粒子、または項目15に記載の薬学的組成物の有効量を、該脊椎動物に投与する工程を包含する、方法。
特定の実施形態では、例えば以下が提供される:
(項目1)
脊椎動物細胞へRNAをインビボで送達するための非ビリオン粒子であって、ここで、
(a)該粒子は、
(i)送達物質であって、免疫原をコードする自己複製RNA分子を被包している、送達物質、または
(ii)送達物質であって、免疫原をコードする自己複製RNA分子が、該送達物質に吸着させられている、送達物質
のいずれかを含み、
(b)該RNAは、改変されたヌクレオチドを含まない、
非ビリオン粒子。
(項目2)
前記粒子が、リポソームであり、前記RNAが、該リポソーム中に被包されている、項目1に記載の粒子。
(項目3)
前記粒子が、非毒性かつ生分解性のポリマー微粒子であり、前記RNAが、該ポリマー微粒子に吸着させられている、項目1に記載の粒子。
(項目4)
前記粒子が、ポリマー、架橋剤、荷電したモノマーおよび前記RNAを反応させることによって形成された、生分解性の架橋されたオリゴマーのポリマーナノ粒子である、項目1に記載の粒子。
(項目5)
前記リポソームが、カチオン性頭部を有する脂質を含む、項目2に記載の粒子。
(項目6)
前記リポソームが、両性イオン性頭部を有する脂質を含む、項目2または項目5に記載の粒子。
(項目7)
前記リポソームが、50nm〜220nmの範囲の直径を有する、項目2、項目5または項目6に記載の粒子。
(項目8)
前記粒子が、ポリ(D,L−ラクチド−co−グリコリド)を含む、項目3に記載の粒子。
(項目9)
前記粒子が、直径30nm〜7μmを有する、項目3または項目8に記載の粒子。
(項目10)
前記自己複製RNA分子が、
(i)該自己複製RNA分子からRNAを転写し得るRNA依存性RNAポリメラーゼ、および
(ii)免疫原
をコードする、前述の項目のいずれかに記載の粒子。
(項目11)
前記RNA分子が、2個のオープンリーディングフレームを有し、該2個のオープンリーディングフレームの第1のものが、アルファウイルスレプリカーゼをコードし、該2個のオープンリーディングフレームの第2のものが、前記免疫原をコードする、項目10に記載の粒子。
(項目12)
前記RNA分子が、9000〜12000ヌクレオチド長である、前述の項目のいずれかに記載の粒子。
(項目13)
前記免疫原が、細菌、ウイルス、真菌もしくは寄生生物に対してインビボで免疫応答を誘
発し得る、前述の項目のいずれかに記載の粒子。
(項目14)
前記免疫原が、RSウイルス糖タンパク質Fに対してインビボで免疫応答を誘発し得る、項目13に記載の粒子。
(項目15)
前述の項目のいずれかに記載の粒子を含む、薬学的組成物。
(項目16)
脊椎動物において防御免疫応答を惹起するための方法であって、該方法は、項目1〜14に記載の粒子、または項目15に記載の薬学的組成物の有効量を、該脊椎動物に投与する工程を包含する、方法。
Claims (17)
- 脊椎動物細胞へRNAをインビボで送達するための非ビリオン粒子であって、ここで、
(a)該粒子は、
(i)送達物質であって、免疫原をコードする自己複製RNA分子を被包している、送達物質、または
(ii)送達物質であって、免疫原をコードする自己複製RNA分子が、該送達物質に吸着させられている、送達物質
のいずれかを含み、
(b)該RNAは、改変されたヌクレオチドを含まない、
非ビリオン粒子。 - 前記粒子が、リポソームであり、前記RNAが、該リポソーム中に被包されている、請求項1に記載の粒子。
- 前記粒子が、非毒性かつ生分解性のポリマー微粒子であり、前記RNAが、該ポリマー微粒子に吸着させられている、請求項1に記載の粒子。
- 前記粒子が、ポリマー、架橋剤、荷電したモノマーおよび前記RNAを反応させることによって形成された、生分解性の架橋されたオリゴマーのポリマーナノ粒子である、請求項1に記載の粒子。
- 前記リポソームが、カチオン性頭部を有する脂質を含む、請求項2に記載の粒子。
- 前記リポソームが、両性イオン性頭部を有する脂質を含む、請求項2または請求項5に記載の粒子。
- 前記リポソームが、50nm〜220nmの範囲の直径を有する、請求項2、請求項5または請求項6に記載の粒子。
- 前記粒子が、ポリ(D,L−ラクチド−co−グリコリド)を含む、請求項3に記載の粒子。
- 前記粒子が、直径30nm〜7μmを有する、請求項3または請求項8に記載の粒子。
- 前記自己複製RNA分子が、
(i)該自己複製RNA分子からRNAを転写し得るRNA依存性RNAポリメラーゼ、および
(ii)免疫原
をコードする、請求項1〜9のいずれか一項に記載の粒子。 - 前記RNA分子が、2個のオープンリーディングフレームを有し、該2個のオープンリーディングフレームの第1のものが、アルファウイルスレプリカーゼをコードし、該2個のオープンリーディングフレームの第2のものが、前記免疫原をコードする、請求項10に記載の粒子。
- 前記RNA分子が、9000〜12000ヌクレオチド長である、請求項1〜11のいずれか一項に記載の粒子。
- 前記免疫原が、細菌、ウイルス、真菌もしくは寄生生物に対してインビボで免疫応答を誘
発し得る、請求項1から12のいずれか一項に記載の粒子。 - 前記免疫原が、RSウイルス糖タンパク質Fに対してインビボで免疫応答を誘発し得る、請求項13に記載の粒子。
- 請求項1〜14のいずれか一項に記載の粒子を含む、薬学的組成物。
- 脊椎動物において防御免疫応答を惹起するための医薬の製造における、請求項1〜14のいずれか一項に記載の粒子、または請求項15に記載の薬学的組成物の使用。
- 脊椎動物において防御免疫応答を惹起するために使用される、請求項15に記載の薬学的組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36182810P | 2010-07-06 | 2010-07-06 | |
US61/361,828 | 2010-07-06 | ||
PCT/US2011/043103 WO2012006376A2 (en) | 2010-07-06 | 2011-07-06 | Virion-like delivery particles for self-replicating rna molecules |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013533747A JP2013533747A (ja) | 2013-08-29 |
JP2013533747A5 true JP2013533747A5 (ja) | 2014-08-07 |
JP6061849B2 JP6061849B2 (ja) | 2017-01-18 |
Family
ID=44629863
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013518813A Active JP6061849B2 (ja) | 2010-07-06 | 2011-07-06 | 自己複製rna分子についてのビリオン様送達粒子 |
Country Status (22)
Country | Link |
---|---|
US (2) | US11291635B2 (ja) |
EP (4) | EP2590676B1 (ja) |
JP (1) | JP6061849B2 (ja) |
CN (2) | CN103052400B (ja) |
AU (1) | AU2011276232B2 (ja) |
BR (1) | BR112013000392B8 (ja) |
CA (1) | CA2804494A1 (ja) |
CY (1) | CY1118080T1 (ja) |
DK (1) | DK2590676T3 (ja) |
ES (2) | ES2934240T3 (ja) |
FI (1) | FI4005592T3 (ja) |
HR (2) | HRP20221522T1 (ja) |
HU (2) | HUE060788T2 (ja) |
LT (2) | LT2590676T (ja) |
MX (1) | MX342608B (ja) |
PL (2) | PL2590676T3 (ja) |
PT (2) | PT4005592T (ja) |
RS (2) | RS63817B1 (ja) |
RU (1) | RU2013104890A (ja) |
SI (2) | SI2590676T1 (ja) |
SM (1) | SMT201600386B (ja) |
WO (1) | WO2012006376A2 (ja) |
Families Citing this family (168)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2804591C (en) | 2010-07-06 | 2019-01-22 | Novartis Ag | Cationic oil-in-water emulsions |
PT2591114T (pt) | 2010-07-06 | 2016-08-02 | Glaxosmithkline Biologicals Sa | Imunização de mamíferos de grande porte com doses baixas de arn |
WO2012006378A1 (en) | 2010-07-06 | 2012-01-12 | Novartis Ag | Liposomes with lipids having an advantageous pka- value for rna delivery |
BR112013000392B8 (pt) | 2010-07-06 | 2022-10-04 | Novartis Ag | Composição farmacêutica contendo partícula de distribuição semelhante a vírion para moléculas de rna autorreplicantes e seu uso |
HUE047796T2 (hu) | 2010-07-06 | 2020-05-28 | Glaxosmithkline Biologicals Sa | RNS bevitele több immunútvonal bekapcsolására |
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
PT4008357T (pt) | 2010-08-31 | 2023-01-11 | Glaxosmithkline Biologicals Sa | Lipossomas pequenos para entrega de arn que codifica um imunogénio |
LT4066855T (lt) | 2010-08-31 | 2023-03-10 | Glaxosmithkline Biologicals Sa | Pegilintos liposomos, skirtos imunogeną koduojančios rnr tiekimui |
PL3590949T3 (pl) | 2010-10-01 | 2022-08-29 | Modernatx, Inc. | Kwasy rybonukleinowe zawierające n1-metylo-pseudouracyle i ich zastosowania |
ES2716243T3 (es) * | 2010-10-11 | 2019-06-11 | Glaxosmithkline Biologicals Sa | Plataformas de suministro de antígenos |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
PT2717893T (pt) | 2011-06-08 | 2019-08-20 | Translate Bio Inc | Composições de nanopartículas lipídicas e métodos para transferência de arnm |
EP2729126B1 (en) * | 2011-07-06 | 2020-12-23 | GlaxoSmithKline Biologicals SA | Liposomes having useful n:p ratio for delivery of rna molecules |
RU2649133C2 (ru) | 2011-07-06 | 2018-03-29 | Новартис Аг | Катионные эмульсии масло-в-воде |
ES2656050T3 (es) | 2011-07-06 | 2018-02-22 | Glaxosmithkline Biologicals Sa | Composiciones de combinación inmunogénica y usos de las mismas |
EP3424495A1 (en) | 2011-07-06 | 2019-01-09 | GlaxoSmithKline Biologicals S.A. | Oil-in-water emulsions that contain nucleic acids |
SG11201400250UA (en) * | 2011-08-31 | 2014-03-28 | Novartis Ag | Pegylated liposomes for delivery of immunogen-encoding rna |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
AU2012318752B2 (en) | 2011-10-03 | 2017-08-31 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
JP6305925B2 (ja) * | 2011-10-11 | 2018-04-18 | ノバルティス アーゲー | 組換え自己複製ポリシストロニックrna分子 |
LT2791160T (lt) | 2011-12-16 | 2022-06-10 | Modernatx, Inc. | Modifikuotos mrnr sudėtys |
US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
WO2013151666A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of biologics and proteins associated with human disease |
AU2013243951A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
JP6561378B2 (ja) | 2012-06-08 | 2019-08-21 | トランスレイト バイオ, インコーポレイテッド | 非肺標的細胞へのmRNAの経肺送達 |
WO2014028429A2 (en) | 2012-08-14 | 2014-02-20 | Moderna Therapeutics, Inc. | Enzymes and polymerases for the synthesis of rna |
JP6144355B2 (ja) | 2012-11-26 | 2017-06-07 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | 化学修飾mRNA |
WO2014108515A1 (en) * | 2013-01-10 | 2014-07-17 | Novartis Ag | Influenza virus immunogenic compositions and uses thereof |
WO2014113089A2 (en) | 2013-01-17 | 2014-07-24 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
EP2968391A1 (en) | 2013-03-13 | 2016-01-20 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
DK2970948T3 (en) | 2013-03-15 | 2019-04-08 | Glaxosmithkline Biologicals Sa | METHODS OF RNA PURIFICATION |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
DK3019619T3 (da) | 2013-07-11 | 2021-10-11 | Modernatx Inc | Sammensætninger, der omfatter syntetiske polynukleotider, som koder for crispr-beslægtede proteiner, og syntetiske sgrna'er, og anvendelsesfremgangsmåder |
CA2923029A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
EP3041938A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Circular polynucleotides |
US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
EA201690675A1 (ru) | 2013-10-03 | 2016-08-31 | Модерна Терапьютикс, Инк. | Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности |
WO2015126477A1 (en) * | 2013-11-08 | 2015-08-27 | Tyrx, Inc. | Polymeric drug delivery system for treating surgical complications |
WO2015144732A2 (en) * | 2014-03-25 | 2015-10-01 | Yale University | Uses of parasite macrophage migration inhibitory factors |
LT3134131T (lt) | 2014-04-23 | 2022-02-10 | Modernatx, Inc. | Nukleorūgšties vakcinos |
EP2974739A1 (en) | 2014-07-15 | 2016-01-20 | Novartis AG | RSVF trimerization domains |
MX2016016533A (es) | 2014-06-13 | 2017-05-01 | Glaxosmithkline Biologicals Sa | Combinaciones inmunogenas. |
JP2017524357A (ja) | 2014-07-16 | 2017-08-31 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | キメラポリヌクレオチド |
EP3171895A1 (en) | 2014-07-23 | 2017-05-31 | Modernatx, Inc. | Modified polynucleotides for the production of intrabodies |
EP3061826A1 (en) | 2015-02-27 | 2016-08-31 | Novartis AG | Flavivirus replicons |
CN108064176A (zh) | 2015-04-22 | 2018-05-22 | 库瑞瓦格股份公司 | 用于治疗肿瘤疾病的含有rna的组合物 |
EP4218805A1 (en) | 2015-07-21 | 2023-08-02 | ModernaTX, Inc. | Infectious disease vaccines |
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
ES2969082T3 (es) | 2015-09-17 | 2024-05-16 | Modernatx Inc | Compuestos y composiciones para la administración intracelular de agentes terapéuticos |
EP3359670B2 (en) | 2015-10-05 | 2024-02-14 | ModernaTX, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
MA45209A (fr) | 2015-10-22 | 2019-04-17 | Modernatx Inc | Vaccins contre les maladies sexuellement transmissibles |
MA46316A (fr) | 2015-10-22 | 2021-03-24 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
CA3003103A1 (en) * | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
MA46317A (fr) * | 2015-10-22 | 2019-08-07 | Modernatx Inc | Vaccin contre le virus respiratoire syncytial |
PE20181531A1 (es) * | 2015-10-22 | 2018-09-26 | Modernatx Inc | Vacuna del virus herpes simple |
TW201729838A (zh) | 2015-10-22 | 2017-09-01 | 現代公司 | 用於水痘帶狀疱疹病毒 (vzv)之核酸疫苗 |
SI3386484T1 (sl) | 2015-12-10 | 2022-06-30 | Modernatx, Inc. | Sestave in metode za dovajanje terapevtskih sredstev |
JP7114465B2 (ja) | 2015-12-22 | 2022-08-08 | モデルナティエックス インコーポレイテッド | 薬剤の細胞内送達のための化合物および組成物 |
RS63135B1 (sr) | 2015-12-23 | 2022-05-31 | Modernatx Inc | Postupci upotrebe polinukleotida koji kodiraju ox40 ligand |
EP3400023A1 (en) | 2016-01-10 | 2018-11-14 | ModernaTX, Inc. | Therapeutic mrnas encoding anti ctla-4 antibodies |
CN108778365B (zh) | 2016-01-11 | 2021-05-25 | 沃达瑞公司 | 微针组合物及其使用方法 |
WO2017162265A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Trans-replicating rna |
US10967057B2 (en) | 2016-06-02 | 2021-04-06 | Glaxosmithkline Biologicals S.A. | Zika viral antigen constructs |
US11466292B2 (en) | 2016-09-29 | 2022-10-11 | Glaxosmithkline Biologicals Sa | Compositions and methods of treatment |
GB201616904D0 (en) | 2016-10-05 | 2016-11-16 | Glaxosmithkline Biologicals Sa | Vaccine |
CA3041307A1 (en) | 2016-10-21 | 2018-04-26 | Giuseppe Ciaramella | Human cytomegalovirus vaccine |
WO2018089540A1 (en) | 2016-11-08 | 2018-05-17 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
EP3538146A4 (en) | 2016-11-11 | 2020-07-15 | ModernaTX, Inc. | INFLUENZA VACCINE |
EP3541416A1 (en) | 2016-11-17 | 2019-09-25 | GlaxoSmithKline Biologicals SA | Zika viral antigen constructs |
EP3551193A4 (en) | 2016-12-08 | 2020-08-19 | Modernatx, Inc. | NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES |
BR112019017743A2 (pt) | 2017-02-28 | 2020-04-07 | Sanofi Sa | rna terapêutico |
WO2018170256A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
MA52262A (fr) | 2017-03-15 | 2020-02-19 | Modernatx Inc | Vaccin à large spectre contre le virus de la grippe |
DK3596042T3 (da) | 2017-03-15 | 2022-04-11 | Modernatx Inc | Krystalformer af aminolipider |
US11464848B2 (en) | 2017-03-15 | 2022-10-11 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
FI3596041T3 (fi) | 2017-03-15 | 2023-01-31 | Yhdiste ja koostumuksia terapeuttisten aineiden antamiseen solun sisään | |
US11045540B2 (en) | 2017-03-15 | 2021-06-29 | Modernatx, Inc. | Varicella zoster virus (VZV) vaccine |
CA3055653A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
CN110612116A (zh) | 2017-05-08 | 2019-12-24 | 磨石肿瘤生物技术公司 | 甲病毒新抗原载体 |
US11485972B2 (en) | 2017-05-18 | 2022-11-01 | Modernatx, Inc. | Modified messenger RNA comprising functional RNA elements |
CA3063723A1 (en) | 2017-05-18 | 2018-11-22 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof |
MA49395A (fr) | 2017-06-14 | 2020-04-22 | Modernatx Inc | Polynucléotides codant pour le facteur viii de coagulation |
JP7402503B2 (ja) | 2017-06-14 | 2023-12-21 | テクニスチェ ユニベルシタト ドレスデン | デザイナーdna組換え酵素を利用したゲノムを遺伝的に改変するための方法及び手段 |
MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
CN111163799A (zh) | 2017-07-28 | 2020-05-15 | 扬森疫苗与预防公司 | 用于异源repRNA免疫接种的方法和组合物 |
US11639329B2 (en) | 2017-08-16 | 2023-05-02 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
CN111315359A (zh) | 2017-08-31 | 2020-06-19 | 摩登纳特斯有限公司 | 制备脂质纳米颗粒的方法 |
WO2019055807A1 (en) | 2017-09-14 | 2019-03-21 | Modernatx, Inc. | RNA VACCINES AGAINST ZIKA VIRUS |
EP3461497A1 (en) | 2017-09-27 | 2019-04-03 | GlaxoSmithKline Biologicals S.A. | Viral antigens |
EP3714047A2 (en) | 2017-11-22 | 2020-09-30 | ModernaTX, Inc. | Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria |
WO2019104195A1 (en) | 2017-11-22 | 2019-05-31 | Modernatx, Inc. | Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia |
CA3079428A1 (en) | 2017-11-22 | 2019-05-31 | Modernatx, Inc. | Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders |
US11021692B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Hepatitis B virus (HBV) vaccines and uses thereof |
US11389531B2 (en) | 2017-12-19 | 2022-07-19 | Janssen Sciences Ireland Unlimited Company | Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines |
US11020476B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV) |
CA3085975A1 (en) | 2017-12-20 | 2019-06-27 | Glaxosmithkline Biologicals Sa | Epstein-barr virus antigen constructs |
CN111818943A (zh) | 2018-01-04 | 2020-10-23 | 伊科尼克治疗公司 | 抗组织因子抗体、抗体-药物缀合物及相关方法 |
MA51523A (fr) | 2018-01-05 | 2020-11-11 | Modernatx Inc | Polynucléotides codant pour des anticorps anti-virus du chikungunya |
MA54676A (fr) | 2018-01-29 | 2021-11-17 | Modernatx Inc | Vaccins à base d'arn contre le vrs |
WO2019217964A1 (en) | 2018-05-11 | 2019-11-14 | Lupagen, Inc. | Systems and methods for closed loop, real-time modifications of patient cells |
WO2019226650A1 (en) | 2018-05-23 | 2019-11-28 | Modernatx, Inc. | Delivery of dna |
EP3581201A1 (en) | 2018-06-15 | 2019-12-18 | GlaxoSmithKline Biologicals S.A. | Escherichia coli o157:h7 proteins and uses thereof |
US20220184185A1 (en) | 2018-07-25 | 2022-06-16 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
CN113164584A (zh) | 2018-08-17 | 2021-07-23 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性组合物及其用途 |
US20220110966A1 (en) | 2018-09-02 | 2022-04-14 | Modernatx, Inc. | Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency |
MA53608A (fr) | 2018-09-13 | 2021-07-21 | Modernatx Inc | Polynucléotides codant pour les sous-unités e1-alpha, e1-beta et e2 du complexe alpha-cétoacide déshydrogénase à chaîne ramifiée pour le traitement de la leucinose |
JP2022500436A (ja) | 2018-09-13 | 2022-01-04 | モダーナティエックス・インコーポレイテッドModernaTX, Inc. | 糖原病を処置するためのグルコース−6−ホスファターゼをコードするポリヌクレオチド |
US20220401584A1 (en) | 2018-09-14 | 2022-12-22 | Modernatx, Inc. | Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome |
EP3856233A1 (en) | 2018-09-27 | 2021-08-04 | Modernatx, Inc. | Polynucleotides encoding arginase 1 for the treatment of arginase deficiency |
TW202043256A (zh) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
JP2022524391A (ja) * | 2019-03-08 | 2022-05-02 | マサチューセッツ インスティテュート オブ テクノロジー | 合成腫瘍溶解性lnpレプリコンrnaおよびがん免疫治療のための使用 |
US20220226438A1 (en) | 2019-05-08 | 2022-07-21 | Astrazeneca Ab | Compositions for skin and wounds and methods of use thereof |
SG11202113187WA (en) | 2019-05-30 | 2021-12-30 | Gritstone Bio Inc | Modified adenoviruses |
CA3143680A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody |
EP3986460A2 (en) | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody |
CN114340664A (zh) | 2019-06-18 | 2022-04-12 | 爱尔兰詹森科学公司 | 乙型肝炎病毒(HBV)疫苗和靶向HBV的RNAi的组合 |
WO2020255014A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Recombinant interleukin 12 construct and uses thereof |
WO2020255010A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines |
AU2020295807A1 (en) * | 2019-06-20 | 2022-02-17 | Janssen Sciences Ireland Unlimited Company | Lipid nanoparticle or liposome delivery of hepatitis B virus (HBV) vaccines |
BR112022000710A2 (pt) | 2019-07-21 | 2022-03-22 | Glaxosmithkline Biologicals Sa | Vacina viral terapêutica |
AU2020350759A1 (en) | 2019-09-19 | 2022-03-31 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
AU2021233816A1 (en) | 2020-03-09 | 2022-10-06 | Arcturus Therapeutics, Inc. | Coronavirus vaccine compositions and methods |
WO2021209970A1 (en) | 2020-04-16 | 2021-10-21 | Glaxosmithkline Biologicals Sa | Sars cov-2 spike protein construct |
CA3184474A1 (en) | 2020-06-01 | 2021-12-09 | Modernatx, Inc. | Phenylalanine hydroxylase variants and uses thereof |
WO2021245611A1 (en) | 2020-06-05 | 2021-12-09 | Glaxosmithkline Biologicals Sa | Modified betacoronavirus spike proteins |
EP4171629A1 (en) | 2020-06-29 | 2023-05-03 | GlaxoSmithKline Biologicals S.A. | Adjuvants |
WO2022008613A1 (en) | 2020-07-08 | 2022-01-13 | Janssen Sciences Ireland Unlimited Company | Rna replicon vaccines against hbv |
KR20230046313A (ko) | 2020-08-06 | 2023-04-05 | 그릿스톤 바이오, 인코포레이티드 | 다중에피토프 백신 카세트 |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
US20230406895A1 (en) | 2020-11-13 | 2023-12-21 | Modernatx, Inc. | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis |
TW202245809A (zh) | 2020-12-18 | 2022-12-01 | 美商詹森藥物公司 | 用於治療b型肝炎病毒感染之組合療法 |
CA3171051A1 (en) * | 2020-12-22 | 2022-06-30 | Curevac Ag | Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration |
EP4267593A2 (en) | 2020-12-23 | 2023-11-01 | GlaxoSmithKline Biologicals SA | Self-amplifying messenger rna |
AU2021412833A1 (en) | 2020-12-28 | 2023-07-06 | Arcturus Therapeutics, Inc. | Transcription activator-like effector nucleases (talens) targeting hbv |
EP4032546A1 (en) | 2021-01-20 | 2022-07-27 | GlaxoSmithKline Biologicals S.A. | Therapeutic viral vaccine |
US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
WO2022204371A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof |
WO2022204390A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof |
WO2022204380A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof |
WO2022204369A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia |
EP4314260A1 (en) | 2021-03-24 | 2024-02-07 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency |
WO2022200574A1 (en) | 2021-03-26 | 2022-09-29 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
WO2022248353A1 (en) | 2021-05-24 | 2022-12-01 | Glaxosmithkline Biologicals Sa | Adjuvants |
EP4352247A1 (en) | 2021-06-09 | 2024-04-17 | GlaxoSmithKline Biologicals s.a. | Release assay for determining potency of self-amplifying rna drug product and methods for using |
EP4355882A2 (en) | 2021-06-15 | 2024-04-24 | Modernatx, Inc. | Engineered polynucleotides for cell-type or microenvironment-specific expression |
WO2022271776A1 (en) | 2021-06-22 | 2022-12-29 | Modernatx, Inc. | Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome |
WO2023020993A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
WO2023021427A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof |
WO2023021421A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Low-dose lyophilized rna vaccines and methods for preparing and using the same |
WO2023020994A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
WO2023020992A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
CN118043466A (zh) | 2021-09-03 | 2024-05-14 | 葛兰素史克生物有限公司 | 自扩增信使核糖核酸中核苷酸碱基的取代 |
WO2023056044A1 (en) | 2021-10-01 | 2023-04-06 | Modernatx, Inc. | Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease |
WO2023056980A1 (zh) * | 2021-10-09 | 2023-04-13 | 吴可行 | 自复制rna分子设计及其应用 |
TW202338091A (zh) | 2021-11-15 | 2023-10-01 | 德勒斯登工業大學 | 用於有效率且特定之基因組編輯的位置專一性重組酶 |
WO2023183909A2 (en) | 2022-03-25 | 2023-09-28 | Modernatx, Inc. | Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia |
WO2023198815A1 (en) | 2022-04-14 | 2023-10-19 | Janssen Vaccines & Prevention B.V. | Sequential administration of adenoviruses |
WO2023218420A1 (en) | 2022-05-13 | 2023-11-16 | Janssen Pharmaceuticals, Inc. | Mrna compositions for inducing latent hiv-1 reversal |
CN117070464A (zh) * | 2022-05-16 | 2023-11-17 | 上海行深生物科技有限公司 | 蛋白包裹自复制rna及其制备方法 |
WO2023233290A1 (en) | 2022-05-31 | 2023-12-07 | Janssen Sciences Ireland Unlimited Company | Rnai agents targeting pd-l1 |
WO2023242817A2 (en) | 2022-06-18 | 2023-12-21 | Glaxosmithkline Biologicals Sa | Recombinant rna molecules comprising untranslated regions or segments encoding spike protein from the omicron strain of severe acute respiratory coronavirus-2 |
WO2024026254A1 (en) | 2022-07-26 | 2024-02-01 | Modernatx, Inc. | Engineered polynucleotides for temporal control of expression |
WO2024068545A1 (en) | 2022-09-26 | 2024-04-04 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
Family Cites Families (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6090406A (en) * | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
US5140086A (en) | 1988-11-25 | 1992-08-18 | Weyerhaeuser Company | Isocyanate modified cellulose products and method for their manufacture |
US6867195B1 (en) | 1989-03-21 | 2005-03-15 | Vical Incorporated | Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US5693535A (en) | 1992-05-14 | 1997-12-02 | Ribozyme Pharmaceuticals, Inc. | HIV targeted ribozymes |
US5750390A (en) | 1992-08-26 | 1998-05-12 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of diseases caused by expression of the bcl-2 gene |
EP0646178A1 (en) | 1992-06-04 | 1995-04-05 | The Regents Of The University Of California | expression cassette with regularoty regions functional in the mammmlian host |
JPH07509133A (ja) | 1992-07-17 | 1995-10-12 | リボザイム・ファーマシューティカルズ・インコーポレイテッド | 動物疾患の処置のための方法および剤 |
EP0702516A4 (en) | 1993-06-01 | 1998-04-22 | Life Technologies Inc | GENETIC IMMUNIZATION WITH CATIONIC LIPIDS |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
AU727923B2 (en) * | 1995-09-27 | 2001-01-04 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Production of infectious respiratory syncytial virus from cloned nucleotide sequences |
JP2001503735A (ja) | 1996-07-03 | 2001-03-21 | ユニバーシティ オブ ピッツバーグ | 親水性活性試薬のためのエマルジョン処方物 |
ATE228824T1 (de) | 1996-09-13 | 2002-12-15 | Lipoxen Technologies Ltd | Liposomenzusammensetzung |
US7384923B2 (en) | 1999-05-14 | 2008-06-10 | Lipoxen Technologies Limited | Liposomes |
US6395302B1 (en) | 1996-11-19 | 2002-05-28 | Octoplus B.V. | Method for the preparation of microspheres which contain colloidal systems |
JP4656675B2 (ja) | 1997-05-14 | 2011-03-23 | ユニバーシティー オブ ブリティッシュ コロンビア | 脂質小胞への荷電した治療剤の高率封入 |
US6060308A (en) | 1997-09-04 | 2000-05-09 | Connaught Laboratories Limited | RNA respiratory syncytial virus vaccines |
US6009406A (en) | 1997-12-05 | 1999-12-28 | Square D Company | Methodology and computer-based tools for re-engineering a custom-engineered product line |
US6432925B1 (en) | 1998-04-16 | 2002-08-13 | John Wayne Cancer Institute | RNA cancer vaccine and methods for its use |
CA2336554A1 (en) | 1998-06-29 | 2000-01-06 | U.S. Medical Research Institute Of Infectious Diseases | Marburg virus vaccines |
EP1541690A3 (en) | 1999-09-09 | 2005-07-27 | CureVac GmbH | Transfer of mRNA using polycationic compounds |
WO2001029233A2 (en) | 1999-10-20 | 2001-04-26 | The Johns Hopkins University School Of Medicine | Chimeric immunogenic compositions and nucleic acids encoding them |
US8541008B2 (en) * | 1999-11-19 | 2013-09-24 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Pharmaceutical compositions and methods to vaccinate against candidiasis |
US20030212022A1 (en) * | 2001-03-23 | 2003-11-13 | Jean-Marie Vogel | Compositions and methods for gene therapy |
US7149665B2 (en) | 2000-04-03 | 2006-12-12 | Browzwear International Ltd | System and method for simulation of virtual wear articles on virtual models |
JP2004504011A (ja) | 2000-04-18 | 2004-02-12 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 細胞外マトリクスポリヌクレオチド、ポリペプチドおよび抗体 |
DE60139690D1 (de) | 2000-07-03 | 2009-10-08 | Novartis Vaccines & Diagnostic | Immunisierung gegen chlamydia pneumoniae |
AU2001290520A1 (en) | 2000-08-01 | 2002-02-13 | The Johns Hokpins University | Intercellular transport protein linked to an antigen as a molecular vaccine |
DE60118228T2 (de) | 2000-09-28 | 2006-12-14 | Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville | Mikropartikel zur verabreichung von heterologen nukleinsäure |
EP2277894A1 (en) | 2000-10-27 | 2011-01-26 | Novartis Vaccines and Diagnostics S.r.l. | Nucleic acids and proteins from streptococcus groups A & B |
US7731975B2 (en) | 2001-01-31 | 2010-06-08 | The United States Of America As Represented By The Secretary Of The Army | Chimeric filovirus glycoprotein |
US7557200B2 (en) | 2001-02-01 | 2009-07-07 | Johns Hopkins University | Superior molecular vaccine based on self-replicating RNA, suicidal DNA or naked DNA vector, that links antigen with polypeptide that promotes antigen presentation |
US20030040498A1 (en) | 2001-03-14 | 2003-02-27 | Ansardi David Calvert | Oncolytic RNA replicons |
US20030077251A1 (en) | 2001-05-23 | 2003-04-24 | Nicolas Escriou | Replicons derived from positive strand RNA virus genomes useful for the production of heterologous proteins |
DE50214200D1 (de) | 2001-06-05 | 2010-03-25 | Curevac Gmbh | Stabilisierte Tumorantigen-mRNA mit erhöhtem G/C-Gehalt |
JP2005506322A (ja) | 2001-08-31 | 2005-03-03 | カイロン ソチエタ ア レスポンサビリタ リミタータ | Helicobacterpyloriワクチン接種 |
ES2330202T5 (es) * | 2001-09-06 | 2014-01-20 | Alphavax, Inc. | Sistemas vectores basados en replicones de alfavirus |
WO2003068190A1 (en) | 2002-02-13 | 2003-08-21 | Northeastern University | Intracellular delivery of therapeutic agents |
DE10207177A1 (de) | 2002-02-19 | 2003-09-04 | Novosom Ag | Fakultativ kationische Lipide |
AU2003245160B2 (en) | 2002-06-28 | 2009-09-24 | Arbutus Biopharma Corporation | Method and apparatus for producing liposomes |
JP2005538186A (ja) | 2002-09-13 | 2005-12-15 | レプリコール インコーポレーティッド | 非配列相補性の抗ウイルス性オリゴヌクレオチド |
CA2508228C (en) | 2002-12-23 | 2013-12-17 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
US8338583B2 (en) | 2003-02-04 | 2012-12-25 | Bar-Ilan University | Snornai-small nucleolar RNA degradation by RNA interference in trypanosomatids |
US7731967B2 (en) | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
JP4623426B2 (ja) | 2003-05-30 | 2011-02-02 | 日本新薬株式会社 | オリゴ核酸担持複合体、当該複合体を含有する医薬組成物 |
RU2352356C2 (ru) | 2003-06-26 | 2009-04-20 | Новартис Вэксинес Энд Дайэгностикс, Инк. | ИММУНОГЕННАЯ КОМПОЗИЦИЯ НА ОСНОВЕ АНТИГЕНА Chlamydia trachomatis (ВАРИАНТЫ) И ЕЕ ИСПОЛЬЗОВАНИЕ |
US7368537B2 (en) * | 2003-07-15 | 2008-05-06 | Id Biomedical Corporation Of Quebec | Subunit vaccine against respiratory syncytial virus infection |
KR101168440B1 (ko) | 2003-07-16 | 2012-07-27 | 프로티바 바이오쎄라퓨틱스, 인코포레이티드 | 지질 캡슐화된 간섭 rna |
JP4875490B2 (ja) | 2003-07-31 | 2012-02-15 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | StreptococcusPyogenesについての免疫原組成物 |
US7303881B2 (en) | 2004-04-30 | 2007-12-04 | Pds Biotechnology Corporation | Antigen delivery compositions and methods of use |
GB0410866D0 (en) | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
AU2005248361B2 (en) | 2004-05-18 | 2010-03-11 | Vical Incorporated | Influenza virus vaccine composition and methods of use |
CA2567254C (en) | 2004-05-18 | 2012-03-13 | Alphavax, Inc. | Tc-83-derived alphavirus vectors, particles and methods |
EP2811027A1 (en) | 2004-05-21 | 2014-12-10 | Novartis Vaccines and Diagnostics, Inc. | Alphavirus vectors for RSV and PIV vaccines |
US7745651B2 (en) | 2004-06-07 | 2010-06-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
JP4796062B2 (ja) | 2004-06-07 | 2011-10-19 | プロチバ バイオセラピューティクス インコーポレイティッド | 脂質封入干渉rna |
WO2006007712A1 (en) * | 2004-07-19 | 2006-01-26 | Protiva Biotherapeutics, Inc. | Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents |
US20080311158A1 (en) | 2004-10-01 | 2008-12-18 | Marcello Merola | Hepatitis C Virus Replication System |
AU2005334819B2 (en) * | 2004-11-15 | 2011-11-24 | Novartis Vaccines And Diagnostics Inc. | Immunogenic compositions containing anthrax antigen, biodegradable polymer microparticles, and polynucleotide-containing immunological adjuvant |
HUE027400T2 (en) | 2005-02-18 | 2016-10-28 | Glaxosmithkline Biologicals Sa | Proteins and nucleic acids from meningitis / sepsis with Escherichia coli |
CA2598488A1 (en) | 2005-02-18 | 2006-08-31 | Novartis Vaccines And Diagnostics, Inc. | Immunogens from uropathogenic escherichia coli |
AU2006219717B2 (en) | 2005-03-02 | 2009-05-21 | The Secretary Of State For Defence | Pharmaceutical composition |
EP1871888A4 (en) | 2005-03-30 | 2013-08-21 | Novartis Vaccines & Diagnostic | HAEMOPHILUS INFLUENZAE TYPE B |
US7618393B2 (en) | 2005-05-03 | 2009-11-17 | Pharmajet, Inc. | Needle-less injector and method of fluid delivery |
CA2608278A1 (en) | 2005-05-12 | 2006-12-28 | Guido Grandi | Immunogenic compositions for chlamydia trachomatis |
US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
TR201909609T4 (tr) | 2005-08-23 | 2019-07-22 | Univ Pennsylvania | Modifiye edilmiş nükleosidleri içeren rna ve kullanım yöntemleri. |
US20110223197A1 (en) | 2005-10-18 | 2011-09-15 | Novartis Vaccines And Diagnostics Inc. | Mucosal and Systemic Immunization with Alphavirus Replicon Particles |
JP2007112768A (ja) | 2005-10-24 | 2007-05-10 | Kyoto Univ | 肝指向性リポソーム組成物 |
WO2007049155A2 (en) | 2005-10-25 | 2007-05-03 | Novartis Vaccines And Diagnostics Srl | Compositions comprising yersinia pestis antigens |
US7915399B2 (en) | 2006-06-09 | 2011-03-29 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
CA2659552A1 (en) | 2006-08-16 | 2008-02-21 | Novartis Ag | Immunogens from uropathogenic escherichia coli |
JP2010519203A (ja) | 2007-02-16 | 2010-06-03 | メルク・シャープ・エンド・ドーム・コーポレイション | 生物活性分子の活性を強化するための組成物及び方法 |
US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
LT2494993T (lt) | 2007-05-04 | 2018-12-27 | Marina Biotech, Inc. | Aminorūgščių lipidai ir jų panaudojimas |
DE102007029471A1 (de) | 2007-06-20 | 2008-12-24 | Novosom Ag | Neue fakultativ kationische Sterole |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
GB0717187D0 (en) | 2007-09-04 | 2007-10-17 | Novartis Ag | Compositions comprising yersinia pestis antigens |
WO2009042794A2 (en) | 2007-09-26 | 2009-04-02 | Vanderbilt University | Venezuelan equine encephalitis replicons expressing paramyxovirus glycoproteins as vaccine |
CA2705787A1 (en) | 2007-11-26 | 2009-06-25 | Novartis Ag | Methods of generating alphavirus particles |
US20110165223A1 (en) | 2008-01-02 | 2011-07-07 | The Johns Hopkins University | Antitumor Immunization by Liposomal Delivery of Vaccine to the Spleen |
CA3044134A1 (en) | 2008-01-02 | 2009-07-09 | Arbutus Biopharma Corporation | Improved compositions and methods for the delivery of nucleic acids |
ITMI20081249A1 (it) | 2008-07-09 | 2010-01-09 | Novartis Vaccines & Diagnostic | Immunogeni di escherichia coli con solubilità migliorata. |
US20110110857A1 (en) | 2008-03-06 | 2011-05-12 | Roberto Petracca | Mutant forms of chlamydia htra |
PL2279254T3 (pl) | 2008-04-15 | 2017-11-30 | Protiva Biotherapeutics Inc. | Nowe preparaty lipidowe do dostarczania kwasów nukleinowych |
WO2009127230A1 (en) | 2008-04-16 | 2009-10-22 | Curevac Gmbh | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION |
WO2009132206A1 (en) | 2008-04-25 | 2009-10-29 | Liquidia Technologies, Inc. | Compositions and methods for intracellular delivery and release of cargo |
US20100040650A1 (en) * | 2008-05-30 | 2010-02-18 | Crowe Jr James E | Virus-Like paramyxovirus particles and vaccines |
EP2130912A1 (en) | 2008-06-04 | 2009-12-09 | Institut für Viruskrankeiten und Immunprophylaxe | Pestivirus replicons providing an RNA-based viral vector system |
CL2008002322A1 (es) | 2008-08-07 | 2009-06-05 | Univ Concepcion | Formulacion farmaceutica veterinaria que comprende un sistema vectorial viral constituido por una particula recombinante de arn que codifica una cu/zn superoxido dismutasa de la bacteria patogena de bovinos brucella abortus, y al menos un alfavirus arn perteneciente a la familia del virus semliki forest (sfv), util como vacuna. |
EP3225621A1 (en) | 2008-10-09 | 2017-10-04 | Arbutus Biopharma Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
AU2009316680B2 (en) | 2008-11-18 | 2016-03-24 | Takeda Vaccines, Inc. | RSV F VLPs and methods of manufacture and use thereof |
BRPI1013780B8 (pt) | 2009-04-14 | 2022-10-04 | Novartis Ag | Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica |
EP2449114B9 (en) | 2009-07-01 | 2017-04-19 | Protiva Biotherapeutics Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
US20120100207A1 (en) | 2009-07-02 | 2012-04-26 | Konica Minolta Holdings, Inc. | Process for producing liposomes by two-step emulsification method utilizing outer aqueous phase containing specific dispersing agent, process for producing liposome dispersion or dry powder thereof using the process for producing liposomes, and liposome dispersion or dry powder thereof produced thereby |
CA2766907A1 (en) | 2009-07-06 | 2011-01-13 | Novartis Ag | Self replicating rna molecules and uses thereof |
HUE058971T2 (hu) * | 2009-07-15 | 2022-09-28 | Glaxosmithkline Biologicals Sa | RSV F fehérjekészítmények és eljárások azok elõállítására |
US8277919B2 (en) | 2009-07-23 | 2012-10-02 | VMO Systems, Inc. | Reflective coating for an optical disc |
KR20120097484A (ko) | 2009-07-31 | 2012-09-04 | 에트리스 게엠베하 | 단백질 발현을 위한 비변형된 뉴클레오티드 및 변형된 뉴클레오티드의 조합을 가진 rna |
CN102712935B (zh) * | 2009-11-04 | 2017-04-26 | 不列颠哥伦比亚大学 | 含有核酸的脂质粒子及相关的方法 |
US20110112353A1 (en) | 2009-11-09 | 2011-05-12 | Circulite, Inc. | Bifurcated outflow cannulae |
LT2506857T (lt) | 2009-12-01 | 2018-07-10 | Translate Bio, Inc. | Mrnr tiekimas baltymų ir fermentų papildymui žmogaus genetinių ligų atvejais |
SG181904A1 (en) | 2009-12-23 | 2012-07-30 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
CA2804591C (en) | 2010-07-06 | 2019-01-22 | Novartis Ag | Cationic oil-in-water emulsions |
HUE047796T2 (hu) | 2010-07-06 | 2020-05-28 | Glaxosmithkline Biologicals Sa | RNS bevitele több immunútvonal bekapcsolására |
BR112013000392B8 (pt) | 2010-07-06 | 2022-10-04 | Novartis Ag | Composição farmacêutica contendo partícula de distribuição semelhante a vírion para moléculas de rna autorreplicantes e seu uso |
WO2012006378A1 (en) | 2010-07-06 | 2012-01-12 | Novartis Ag | Liposomes with lipids having an advantageous pka- value for rna delivery |
PT2591114T (pt) | 2010-07-06 | 2016-08-02 | Glaxosmithkline Biologicals Sa | Imunização de mamíferos de grande porte com doses baixas de arn |
LT4066855T (lt) | 2010-08-31 | 2023-03-10 | Glaxosmithkline Biologicals Sa | Pegilintos liposomos, skirtos imunogeną koduojančios rnr tiekimui |
BR112013004865A2 (pt) | 2010-08-31 | 2016-06-07 | Novartis Ag | lípidos adequados para entrega lipossomal de codificadores de proteínas rna |
PT4008357T (pt) | 2010-08-31 | 2023-01-11 | Glaxosmithkline Biologicals Sa | Lipossomas pequenos para entrega de arn que codifica um imunogénio |
EP2729126B1 (en) | 2011-07-06 | 2020-12-23 | GlaxoSmithKline Biologicals SA | Liposomes having useful n:p ratio for delivery of rna molecules |
SG11201400250UA (en) | 2011-08-31 | 2014-03-28 | Novartis Ag | Pegylated liposomes for delivery of immunogen-encoding rna |
-
2011
- 2011-07-06 BR BR112013000392A patent/BR112013000392B8/pt active IP Right Grant
- 2011-07-06 LT LTEP11741348.4T patent/LT2590676T/lt unknown
- 2011-07-06 PT PT212041552T patent/PT4005592T/pt unknown
- 2011-07-06 PT PT117413484T patent/PT2590676T/pt unknown
- 2011-07-06 PL PL11741348T patent/PL2590676T3/pl unknown
- 2011-07-06 WO PCT/US2011/043103 patent/WO2012006376A2/en active Application Filing
- 2011-07-06 MX MX2013000089A patent/MX342608B/es active IP Right Grant
- 2011-07-06 ES ES21204155T patent/ES2934240T3/es active Active
- 2011-07-06 RU RU2013104890/15A patent/RU2013104890A/ru unknown
- 2011-07-06 RS RS20221148A patent/RS63817B1/sr unknown
- 2011-07-06 SI SI201130994A patent/SI2590676T1/sl unknown
- 2011-07-06 HU HUE21204155A patent/HUE060788T2/hu unknown
- 2011-07-06 LT LTEP21204155.2T patent/LT4005592T/lt unknown
- 2011-07-06 CA CA2804494A patent/CA2804494A1/en active Pending
- 2011-07-06 EP EP11741348.4A patent/EP2590676B1/en not_active Revoked
- 2011-07-06 CN CN201180033479.3A patent/CN103052400B/zh active Active
- 2011-07-06 CN CN201610906410.1A patent/CN106421773A/zh active Pending
- 2011-07-06 EP EP21204155.2A patent/EP4005592B1/en active Active
- 2011-07-06 AU AU2011276232A patent/AU2011276232B2/en active Active
- 2011-07-06 HR HRP20221522TT patent/HRP20221522T1/hr unknown
- 2011-07-06 JP JP2013518813A patent/JP6061849B2/ja active Active
- 2011-07-06 ES ES11741348.4T patent/ES2600892T3/es active Active
- 2011-07-06 US US13/808,089 patent/US11291635B2/en active Active
- 2011-07-06 PL PL21204155.2T patent/PL4005592T3/pl unknown
- 2011-07-06 DK DK11741348.4T patent/DK2590676T3/en active
- 2011-07-06 EP EP16184271.1A patent/EP3115061A1/en not_active Withdrawn
- 2011-07-06 SI SI201132073T patent/SI4005592T1/sl unknown
- 2011-07-06 RS RS20160879A patent/RS55260B1/sr unknown
- 2011-07-06 EP EP22200367.5A patent/EP4180057A1/en active Pending
- 2011-07-06 HU HUE11741348A patent/HUE031485T2/en unknown
- 2011-07-06 FI FIEP21204155.2T patent/FI4005592T3/fi active
-
2016
- 2016-10-10 CY CY20161101007T patent/CY1118080T1/el unknown
- 2016-10-17 HR HRP20161352TT patent/HRP20161352T1/hr unknown
- 2016-10-27 SM SM201600386T patent/SMT201600386B/it unknown
-
2022
- 2022-03-01 US US17/683,931 patent/US20220192997A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2013533747A5 (ja) | ||
Shin et al. | COVID-19 vaccine development and a potential nanomaterial path forward | |
Lundstrom | Replicon RNA viral vectors as vaccines | |
RU2013104890A (ru) | Вирионоподобные частицы для доставки самореплицирующихся молекул рнк | |
Ma et al. | A review of fish vaccine development strategies: Conventional methods and modern biotechnological approaches | |
Hess et al. | Phage display as a tool for vaccine and immunotherapy development | |
JP2014525461A5 (ja) | ||
Ye et al. | Current status of COVID‐19 (pre) clinical vaccine development | |
JP2014520806A5 (ja) | ||
Schirrmacher | Immunobiology of Newcastle disease virus and its use for prophylactic vaccination in poultry and as adjuvant for therapeutic vaccination in cancer patients | |
Rodríguez-Gascón et al. | Development of nucleic acid vaccines: use of self-amplifying RNA in lipid nanoparticles | |
Zhao et al. | IgA response and protection following nasal vaccination of chickens with Newcastle disease virus DNA vaccine nanoencapsulated with Ag@ SiO2 hollow nanoparticles | |
Jafari et al. | Current advances and challenges in COVID-19 vaccine development: from conventional vaccines to next-generation vaccine platforms | |
FI4043040T3 (fi) | Pieniä liposomeja immunogeeniä koodaavan rna:n toimittamiseksi | |
JP2013538569A5 (ja) | ||
AU2017297822B2 (en) | Formulation for administration of RNA | |
Coughlan et al. | Adenovirus-based vaccines—a platform for pandemic preparedness against emerging viral pathogens | |
Acosta-Coley et al. | Vaccines platforms and COVID-19: what you need to know | |
Chavda et al. | mRNA-based vaccine for COVID-19: they are new but not unknown! | |
Papukashvili et al. | Self-amplifying RNA approach for protein replacement therapy | |
JP2010538619A5 (ja) | ||
Xu et al. | Nanotechnology for the management of COVID-19 during the pandemic and in the post-pandemic era | |
Kembou-Ringert et al. | Tilapia lake virus vaccine development: a review on the recent advances | |
Sadiq et al. | Role of nanoparticles in tackling COVID-19 pandemic: a bio-nanomedical approach | |
Lu et al. | Development of foot-and-mouth disease vaccines in recent years |